share_log

Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio

Moomoo 24/7 ·  Jan 18 06:56

United States Court Of Appeals For The Federal Circuit Affirmed The Previously Announced Decision By The United States District Court For The District Of Delaware Finding That Drug Applications Referencing Eagle Pharmaceuticals' Belrapzo (Bendamustine) Filed By Slayback Pharma And Apotex Did Not Infringe Eagle's Previously Issued '483 Patent

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment